PRODUCT RECALL ALERT

DRAP ALERT NO. Nº II/S/10-23-42

RECALL ALERT OF DOLOR DS SUSPENSION (Batch #1236,1237 and 1238)

(MANUFACTURED BY ADAMJEE PHARMACEUTICALS, KARACHI)

Date: 30th November, 2023

Target Audience:

- Pharmacists and Chemists at Distribution, Pharmacies and Medical Stores
- Healthcare Professionals- Physicians, Pharmacists, and Nurses at hospital and clinics etc.
- General Public

Alert Summary:

Federal Government Analyst, CDL Karachi has declared the 03 Batches of product "Dolor DS Suspension" as of **substandard** quality

The detail of the affected product is as under:

Product Name	Composition	Batch	Manufactured by:	Remarks of CDL
Dolor DS Suspension Reg.No 14451	Mefenamic Acid	Batch No. **1236, 1237, 1238** Mfg. Date: 03-23 Exp. date: 03-25	Ms. Adamjee Pharmaceuticals (Pvt.) Ltd, Karachi	The sample is of Sub-standard quality (on basis of pH and assay test which does not comply with acceptance criteria).

Risk Statement:

Mefenamic acid is used for the short-term relief of mild to moderate pain from various conditions such as headache, dental pain, menstrual cramps, and muscle aches. Inaccurate use of the product may lead to common side effects like skin rash, fever, swollen glands, muscle aches, severe weakness, unusual bruising, or yellowing of your skin or eyes.

Impact of use of substandard product on basis of pH test may significantly altered the solubility and interfere with its absorption which may leads to sub optimal therapeutic effect

DRAP, Islamabad | 92 51 9107404 | gsms@dra.gov.pk

Action Initiated: -

The manufacturer has been directed to immediately recall the defective batch of product from the market. All pharmacists and chemists working at distributions and pharmacies should **immediately check** their stocks and stop supplying these batches of product. The remaining stock should be quarantined and returned to the supplier/ company. The regulatory field force of all federating units (DRAP and Provincial Health Departments) has also increased surveillance in the market to ensure the effective recall of defective products(s).

-Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the **online form**, or through phone at +92 51 910 73 17, or by Email at gsms@dra.gov.pk.

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this affected batch of product.

Adverse reactions or quality problems experienced with the use of this product should be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link

Advice for Consumers / General public: -

Consumers should stop using this product bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre, through MedSafety Mobile Application, or online at Med Vigilance E Reporting System.

All therapeutic goods must be obtained from the licensed pharmacies, and other authorized retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professional in case of any doubt.

Drug Regulatory Authority of Pakistan
محفوظ، موثر اور معیاری اشیائے علاج

DRAP, Islamabad | 92 51 9107404 | gsms@dra.gov.pk